Back to: FDA Improving Anaphylaxis Outcomes: Approaches for Enhancing Access to Epinephrine
Welcome and Overview
Valerie J. Parker
Duke-Margolis Institute for Health Policy
FDA Opening Remarks
Mary Thanh Hai
U.S. Food and Drug Administration
Session 1: Allergic Diseases, Anaphylaxis, and Treatment of Anaphylaxis in the Community Setting:
This session will feature presentations on the latest clinical guidelines and current practices for diagnosing allergic diseases and anaphylaxis. Panel discussion will explore how these practices are referenced to advise individuals on when to carry and administer epinephrine. Challenges to recognizing anaphylaxis and challenges experienced by individuals carrying epinephrine or administering undesignated epinephrine will also be explored.
Moderator
Paul Greenberger
Northwestern University
Presenters:
Hugh Sampson
Icahn School of Medicine at Mount Sinai
Julie Wang
Icahn School of Medicine at Mount Sinai
Panelists:
Hemant Sharma
Children’s National Hospital
Brian Vickery
Emory University